JP6692300B2 - 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 - Google Patents

腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 Download PDF

Info

Publication number
JP6692300B2
JP6692300B2 JP2016574402A JP2016574402A JP6692300B2 JP 6692300 B2 JP6692300 B2 JP 6692300B2 JP 2016574402 A JP2016574402 A JP 2016574402A JP 2016574402 A JP2016574402 A JP 2016574402A JP 6692300 B2 JP6692300 B2 JP 6692300B2
Authority
JP
Japan
Prior art keywords
squalamine
aminosterol
composition
registered trademark
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016574402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519775A5 (enExample
JP2017519775A (ja
Inventor
ザスロフ，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017519775A publication Critical patent/JP2017519775A/ja
Publication of JP2017519775A5 publication Critical patent/JP2017519775A5/ja
Application granted granted Critical
Publication of JP6692300B2 publication Critical patent/JP6692300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2016574402A 2014-06-23 2015-06-22 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 Active JP6692300B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US62/015,657 2014-06-23
US14/329,627 2014-07-11
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020007206A Division JP7010979B2 (ja) 2014-06-23 2020-01-21 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物

Publications (3)

Publication Number Publication Date
JP2017519775A JP2017519775A (ja) 2017-07-20
JP2017519775A5 JP2017519775A5 (enExample) 2018-06-07
JP6692300B2 true JP6692300B2 (ja) 2020-05-13

Family

ID=54869043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016574402A Active JP6692300B2 (ja) 2014-06-23 2015-06-22 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物
JP2020007206A Active JP7010979B2 (ja) 2014-06-23 2020-01-21 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020007206A Active JP7010979B2 (ja) 2014-06-23 2020-01-21 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物

Country Status (19)

Country Link
US (10) US10040817B2 (enExample)
EP (1) EP3157531B1 (enExample)
JP (2) JP6692300B2 (enExample)
CN (2) CN113559108A (enExample)
BR (1) BR112016029917A2 (enExample)
CA (1) CA2951720C (enExample)
CY (1) CY1124554T1 (enExample)
DK (1) DK3157531T3 (enExample)
ES (1) ES2878077T3 (enExample)
HR (1) HRP20211005T1 (enExample)
HU (1) HUE054828T2 (enExample)
LT (1) LT3157531T (enExample)
MX (2) MX382442B (enExample)
PL (1) PL3157531T3 (enExample)
PT (1) PT3157531T (enExample)
RS (1) RS62064B1 (enExample)
SI (1) SI3157531T1 (enExample)
SM (1) SMT202100373T1 (enExample)
WO (1) WO2015200195A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
US20180344748A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating chronic inflammatory diseases
US11083735B2 (en) * 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
MA50536A (fr) 2017-10-30 2020-09-09 Enterin Inc Nouvelles formes solides de squalamine et procédés pour les produire
CN112312917A (zh) * 2018-03-27 2021-02-02 因特尔公司 用于治疗幻觉及其相关病症的方法和组合物
US20190381071A1 (en) * 2018-06-13 2019-12-19 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
EP3829537A4 (en) * 2018-08-03 2022-09-21 Enterin, Inc. LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
ATE169930T1 (de) 1993-03-10 1998-09-15 Magainin Pharma Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
WO1996008270A2 (en) 1994-09-13 1996-03-21 Magainin Pharmaceuticals Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
PT832094E (pt) * 1995-06-07 2004-06-30 Genaera Corp Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
DK0910382T3 (da) 1996-04-26 2003-10-06 Genaera Corp Squalamin i kombination med andre anticancermidler til behandling af tumorer
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
CA2255856C (en) 1996-05-17 2008-05-13 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
AU5194998A (en) 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
EP1105407B1 (en) 1998-08-12 2007-10-10 Genaera Corporation Aminosterol compounds and uses thereof
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002044324A2 (en) * 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
CA2606077C (en) 2005-04-25 2013-07-09 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
WO2009032321A2 (en) 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
JP6165843B2 (ja) 2012-04-20 2017-07-19 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
US10633413B2 (en) 2020-04-28
CY1124554T1 (el) 2022-07-22
DK3157531T3 (da) 2021-07-05
PL3157531T3 (pl) 2021-11-15
MX2016017368A (es) 2017-08-24
US20180319837A1 (en) 2018-11-08
US11440936B2 (en) 2022-09-13
SMT202100373T1 (it) 2021-07-12
US10208080B2 (en) 2019-02-19
EP3157531A1 (en) 2017-04-26
US10208079B2 (en) 2019-02-19
US10196420B2 (en) 2019-02-05
CA2951720A1 (en) 2015-12-30
MX2021005489A (es) 2021-06-18
US20150368290A1 (en) 2015-12-24
US10040817B2 (en) 2018-08-07
MX382442B (es) 2025-03-13
CN106535902A (zh) 2017-03-22
US10975116B2 (en) 2021-04-13
EP3157531B1 (en) 2021-03-31
BR112016029917A2 (pt) 2017-08-22
JP7010979B2 (ja) 2022-02-10
US20220220148A1 (en) 2022-07-14
SI3157531T1 (sl) 2021-09-30
JP2020097587A (ja) 2020-06-25
CA2951720C (en) 2023-09-26
WO2015200195A1 (en) 2015-12-30
HUE054828T2 (hu) 2021-10-28
HRP20211005T1 (hr) 2021-09-17
US20180002370A1 (en) 2018-01-04
CN113559108A (zh) 2021-10-29
US20190185513A1 (en) 2019-06-20
LT3157531T (lt) 2021-07-12
PT3157531T (pt) 2021-07-01
RS62064B1 (sr) 2021-07-30
US20190194243A1 (en) 2019-06-27
ES2878077T3 (es) 2021-11-18
EP3157531A4 (en) 2018-05-16
US20180327445A1 (en) 2018-11-15
JP2017519775A (ja) 2017-07-20
US20170327530A1 (en) 2017-11-16
CN106535902B (zh) 2021-05-25
US20170326156A1 (en) 2017-11-16
US20190194244A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
JP7010979B2 (ja) 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物
US11083735B2 (en) Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US20240058353A1 (en) Methods for treating gi tract disorders
US11834445B2 (en) Polymorphic forms of metopimazine
HK1236807B (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
KR20200115562A (ko) 삼차 신경통의 예방 및 치료를 위한 nep 및 apn 의 저해제로서 디술파닐기를 함유하는 아미노산 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200414

R150 Certificate of patent or registration of utility model

Ref document number: 6692300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250